NEXT Global: Study Builds at Pandemic Speed

NEXT Global

Study Builds at Pandemic Speed
The Evolving Global Landscape of Clinical Trials

The need to rapidly develop both a preventive and therapeutic intervention against COVID-19 has propelled the pharmaceutical industry into action.

The demand for the reduction in study build times requires agile adoption of technology, process, and resources. Speed, without impacting quality and regulatory requirements, has never been more critical. Sponsors and CROs, such as Catalyst Clinical Research, are utilizing Medidata best in class technology and our rapid study build methodologies to shorten their study builds from 14 weeks to just 4 weeks to ensure fast study starts without impacting quality.

In this Medidata NEXT Global session, Medidata’s senior director of client engagement, Edward Ford, together with Corey Harrison, data analyst at Catalyst Clinical Research, LLC, talk about how they utilized Medidata Rave EDC and Rave Coder along with Medidata’s study build expertise to expedite their COVID-19 studies.

Study Builds at Pandemic Speed<br><span>The Evolving Global Landscape of Clinical Trials</span>